JP2009515553A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009515553A5 JP2009515553A5 JP2008541268A JP2008541268A JP2009515553A5 JP 2009515553 A5 JP2009515553 A5 JP 2009515553A5 JP 2008541268 A JP2008541268 A JP 2008541268A JP 2008541268 A JP2008541268 A JP 2008541268A JP 2009515553 A5 JP2009515553 A5 JP 2009515553A5
- Authority
- JP
- Japan
- Prior art keywords
- test kit
- cells
- solution
- vegfr
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 239000000523 sample Substances 0.000 claims 7
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 6
- 108091008605 VEGF receptors Proteins 0.000 claims 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 claims 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002934 lysing effect Effects 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000001235 sensitizing effect Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 238000009396 hybridization Methods 0.000 claims 1
- 230000003100 immobilizing effect Effects 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73585405P | 2005-11-14 | 2005-11-14 | |
| PCT/US2006/044117 WO2007059094A2 (en) | 2005-11-14 | 2006-11-14 | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009515553A JP2009515553A (ja) | 2009-04-16 |
| JP2009515553A5 true JP2009515553A5 (enExample) | 2009-12-10 |
Family
ID=37814675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008541268A Pending JP2009515553A (ja) | 2005-11-14 | 2006-11-14 | 癌の予知および予後と、癌治療のモニタリング |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20070178494A1 (enExample) |
| EP (1) | EP1963849A2 (enExample) |
| JP (1) | JP2009515553A (enExample) |
| KR (1) | KR20080073745A (enExample) |
| CN (1) | CN101454668A (enExample) |
| AU (1) | AU2006315592A1 (enExample) |
| BR (1) | BRPI0618597A2 (enExample) |
| CA (1) | CA2629860A1 (enExample) |
| MX (1) | MX2008006239A (enExample) |
| RU (1) | RU2008123406A (enExample) |
| WO (1) | WO2007059094A2 (enExample) |
| ZA (1) | ZA200804509B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE538794T1 (de) | 1999-01-13 | 2012-01-15 | Bayer Healthcare Llc | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| MXPA04007832A (es) | 2002-02-11 | 2005-09-08 | Bayer Pharmaceuticals Corp | Aril-ureas con actividad inhibitoria de angiogenesis. |
| UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
| EP1636585B2 (en) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
| HRP20060073B1 (hr) | 2003-07-23 | 2014-03-14 | Bayer Healthcare Llc | Fluoro supstituirana omega-karboksiaril difenil urea za lijeäśenje i prevenciju bolesti i stanja |
| CN104688697A (zh) | 2005-03-07 | 2015-06-10 | 拜尔健康护理有限责任公司 | 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物 |
| WO2007047955A2 (en) * | 2005-10-21 | 2007-04-26 | Bayer Healthcare Llc | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
| BRPI0618564A2 (pt) * | 2005-11-02 | 2011-09-06 | Bayer Healthcare Llc | métodos para predição e prognóstico de cáncer e para monitoração de terapia contra cáncer |
| EP2061906B1 (en) * | 2006-09-12 | 2011-08-31 | Genentech, Inc. | Methods and compositions for the diagnosis and treatment of lung cancer using pdgfra, kit or kdr gene as genetic marker |
| AR062927A1 (es) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| US20100311106A1 (en) * | 2008-01-25 | 2010-12-09 | Hartmann Lynn C | Quantitation of lobular involution for breast cancer risk prediction |
| GB0814722D0 (en) * | 2008-08-12 | 2008-09-17 | Ge Healthcare Ltd | Treatment monitoring |
| EP2156834A1 (en) * | 2008-08-08 | 2010-02-24 | S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. | Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye |
| CA2741087A1 (en) * | 2008-10-21 | 2010-04-29 | Bayer Healthcare Llc | Identification of signature genes associated with hepatocellular carcinoma |
| WO2011042829A1 (en) * | 2009-10-07 | 2011-04-14 | Koninklijke Philips Electronics N.V. | Method of evaluating toxicity level of a patient undergoing a cancer treatment |
| CN102053150B (zh) * | 2009-10-30 | 2013-07-17 | 上海交通大学医学院附属瑞金医院 | 一种人成骨肉瘤干细胞相关抗原标记物及其应用 |
| EP2596363B1 (en) * | 2010-07-19 | 2017-01-18 | F. Hoffmann-La Roche AG | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer |
| WO2012016948A1 (en) * | 2010-08-02 | 2012-02-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Novel methods for predicting the responsiveness of a patient affected with a tumor to a treatment with a tyrosine kinase inhibitor |
| CN103459597B (zh) * | 2010-12-13 | 2016-03-30 | 社会福祉法人三星生命公益财团 | 用于预测胃癌预后的标记和使用该标记预测胃癌预后的方法 |
| DK3141617T3 (en) * | 2011-01-11 | 2019-02-25 | Inst Nat Sante Rech Med | PROCEDURE FOR PREVENTING THE CANCER OF A CANCER ON A PATIENT BY ANALYZING GENEPRESSION |
| WO2013173384A1 (en) * | 2012-05-16 | 2013-11-21 | Dale Wong | Method and system for sorting biological samples |
| KR102241063B1 (ko) * | 2013-03-15 | 2021-04-16 | 얀센 파마슈티카 엔.브이. | 예측성 바이오마커에 대한 검정법 |
| US10017823B2 (en) * | 2013-04-25 | 2018-07-10 | Cbs Bioscience, Co., Ltd | Analytical method for increasing susceptibility of molecular targeted therapy in hepatocellular carcinoma |
| RU2546035C1 (ru) * | 2014-04-15 | 2015-04-10 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ прогнозирования развития метастазов у больных меланомой кожи |
| RU2643761C1 (ru) * | 2017-08-10 | 2018-02-05 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ расчета прогноза раннего прогрессирования меланомы кожи |
| WO2019074920A1 (en) * | 2017-10-10 | 2019-04-18 | Oncocyte Corporation | METHODS AND COMPOSITIONS FOR THE DETECTION AND DIAGNOSIS OF BREAST CANCER |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6635421B1 (en) * | 1997-12-09 | 2003-10-21 | Children's Medical Center Corporation | Neuropilins and use thereof in methods for diagnosis and prognosis of cancer |
| US20030232400A1 (en) * | 2002-12-20 | 2003-12-18 | Susan Radka | Methods of screening subjects for expression of soluble receptors of vascular endothelial growth factor (VEGF) for use in managing treatment and determining prognostic outcome |
| WO2005009367A2 (en) * | 2003-07-17 | 2005-02-03 | Ambit Biosciences Corporation | Treatment of diseases with kinase inhibitors |
| US20050267060A1 (en) * | 2004-03-19 | 2005-12-01 | The Penn State Research Foundation | Combinatorial methods and compositions for treatment of melanoma |
-
2006
- 2006-11-14 AU AU2006315592A patent/AU2006315592A1/en not_active Abandoned
- 2006-11-14 CA CA002629860A patent/CA2629860A1/en not_active Abandoned
- 2006-11-14 RU RU2008123406/15A patent/RU2008123406A/ru not_active Application Discontinuation
- 2006-11-14 KR KR1020087014220A patent/KR20080073745A/ko not_active Withdrawn
- 2006-11-14 MX MX2008006239A patent/MX2008006239A/es not_active Application Discontinuation
- 2006-11-14 EP EP06837519A patent/EP1963849A2/en not_active Withdrawn
- 2006-11-14 JP JP2008541268A patent/JP2009515553A/ja active Pending
- 2006-11-14 US US11/598,824 patent/US20070178494A1/en not_active Abandoned
- 2006-11-14 CN CNA2006800505936A patent/CN101454668A/zh active Pending
- 2006-11-14 WO PCT/US2006/044117 patent/WO2007059094A2/en not_active Ceased
- 2006-11-14 BR BRPI0618597-5A patent/BRPI0618597A2/pt not_active IP Right Cessation
-
2008
- 2008-05-23 ZA ZA200804509A patent/ZA200804509B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009515553A5 (enExample) | ||
| Lasserre et al. | SARS-CoV-2 aptasensors based on electrochemical impedance spectroscopy and low-cost gold electrode substrates | |
| Le et al. | Dual recognition element lateral flow assay toward multiplex strain specific influenza virus detection | |
| Zhou et al. | Long non-coding RNA ANRIL regulates inflammatory responses as a novel component of NF-κB pathway | |
| ES2538504T3 (es) | Marcadores en la orina para la detección del cáncer de vejiga | |
| US20110301046A1 (en) | Methods of Determining Efficacy of Glucocorticoid Treatment of Eosinophilic Esophagitis | |
| JP2011528903A5 (enExample) | ||
| JP2012526554A5 (enExample) | ||
| KR20080114689A (ko) | 증가된 ｂｃｌ-2에 의한 암의 발견 | |
| JP2019500582A5 (enExample) | ||
| FI2398902T3 (fi) | Menetelmiä ja koostumuksia syövän diagnoosia ja hoitoa varten | |
| ES2747381T3 (es) | Biomarcador de hipertensión pulmonar | |
| Panta et al. | Salivary RNA signatures in oral cancer detection | |
| JP2013178260A5 (enExample) | ||
| JP2013508719A5 (enExample) | ||
| Jalali et al. | Aptamer based diagnosis of crimean-congo hemorrhagic fever from clinical specimens | |
| Saber et al. | Lack of acute phase response in the livers of mice exposed to diesel exhaust particles or carbon black by inhalation | |
| EP4237850A1 (en) | Improved assays to quantify chromatin targets using antibody-targeted enzyme digestion | |
| JP2022515221A (ja) | クロマチンマッピングアッセイ用のｄｎａバーコード化ヌクレオソーム | |
| JP2011519030A5 (enExample) | ||
| Bao et al. | Prediction of protein–DNA complex mobility in gel-free capillary electrophoresis | |
| Pereira et al. | Enlarging the toolbox against antimicrobial resistance: aptamers and CRISPR-Cas | |
| US20210130890A1 (en) | Synthetic Strands For Nucleic Acid Sequencing And Related Methods And Systems | |
| JP2008547006A5 (enExample) | ||
| CN101666805A (zh) | 特异性蛋白检测芯片的制备方法 |